Nanologica AB (publ) (STO:NICA)
0.5760
+0.0080 (1.41%)
Jun 11, 2026, 5:24 PM CET
Nanologica AB Revenue
Nanologica AB had revenue of 21.46M SEK in the quarter ending March 31, 2026, with 99.57% growth. This brings the company's revenue in the last twelve months to 31.83M, up 57.18% year-over-year. In the year 2025, Nanologica AB had annual revenue of 21.13M with 45.32% growth.
Revenue (ttm)
31.83M
Revenue Growth
+57.18%
P/S Ratio
5.95
Revenue / Employee
442.11K
Employees
72
Market Cap
189.37M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 21.13M | 6.59M | 45.32% |
| Dec 31, 2024 | 14.54M | 9.87M | 211.17% |
| Dec 31, 2023 | 4.67M | -1.16M | -19.92% |
| Dec 31, 2022 | 5.83M | -8.91M | -60.43% |
| Dec 31, 2021 | 14.75M | -3.59M | -19.58% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Xbrane Biopharma AB | 76.45M |
| Elicera Therapeutics AB | 10.64M |
| NextCell Pharma AB | 9.24M |
| Simris Group AB (PUBL) | 2.65M |
| Xintela AB | 2.59M |
| Alligator Bioscience AB | 520.00K |
| Diamyd Medical AB | 362.00K |
Nanologica AB News
- 22 days ago - Nanologica AB Quarterly report: Q1 2026 - Filings
- 3 months ago - Nanologica AB Quarterly report: Q4 2025 - Filings
- 3 months ago - Nanologica AB Annual report: Q4 2025 - Filings
- 8 months ago - Nanologica AB Quarterly report: Q3 2025 - Filings
- 1 year ago - Nanologica AB Quarterly report: Q2 2025 - Filings